Single Use Bioreactor Market Overview

The single use bioreactor market is anticipated to experience substantial growth from 2025 to 2035, fuelled by growing demand for quality products has encouraged biologic manufacturers to adopt single-use bioreactors. With an estimated valuation of approximately USD 4.1 billion in 2025, the market is expected to reach USD 15.1 billion by 2035, registering a robust compound annual growth rate (CAGR) of 12.6% over the decade.

Single-use bioreactors are advanced, disposable bioreactors employed mostly in the production of biopharmaceuticals for culturing cells and manufacturing biologics in the form of monoclonal antibodies, vaccines, and gene therapy. In contrast to stainless-steel bioreactors, SUBs employ sterilized plastic bags in a rigid frame that reduces the cleaning and sterilization process to a bare minimum, lowering turnaround time and the cost of operation considerably.

These systems are conducive to flexible production and are best suited for multi-product and small-batch manufacturing, particularly in early-stage development, clinical trials, and research. SUBs have multiple configurations—stirred-tank, wave-induced, and bubble-column—each designed for specific cell cultures: mammalian, bacterial, and yeast. These systems provide benefits such as minimized risk of contamination, less capital investment, and ease of expansion that have made their use very common in the case of contract manufacturing organizations (CMOs), biotechnology companies, and the drug industry.

The single-use bioreactor market has experienced significant expansion in recent times due to the increasing need for biologics and the move towards modular and adaptive bioproduction plants. North America and Europe have the highest adoption rates due to established biotech industries, but the Asia-Pacific region has the potential to grow strongly. Despite this expansion, areas of material compatibility, waste management strategies, and capacity in larger-scale production still require to be tackled. In summary, single-use bioreactors are a revolutionary leap in terms of bioprocessing because they facilitate accelerated timelines in developing biologics, cost savings, and manufacturing process agility as a result.

Single Use Bioreactor Market Drivers and Opportunities

Rising Demand for Biologics and Personalized Medicine is anticipated to lift the Single Use Bioreactor Market during the forecast period

​ The upsurge in the need for biologics—like monoclonal antibodies, recombinant proteins, and gene therapies—is a key impetus for the single-use bioreactor (SUB) market. Such biologics need highly controlled and contamination-free conditions to enable production, which SUBs provide in the form of pre-sterilized and disposable elements. With the focus of the drug companies leaning towards personalized medicine that involves small-batch and versatile production, SUBs are even more beneficial given their adaptability and fast turnaround. The minimized downtime and setup involved in SUBs enable quicker production cycles to produce desired results sooner. They are perfect for addressing increasing and diverse demands in biologics production.

Cost and Time Efficiency in Bioprocessing drives global Single Use Bioreactor Market

SUBs save a considerable amount of capital investment in terms of infrastructure, cleaning, sterilization, and validation in contrast to conventional stainless-steel systems. They are most appealing to emerging biotechs and contract manufacturing organizations (CMOs) due to this affordability. They also lower the risks of cross-contamination and simplify the workflow by ridding the system of the need for elaborate cleaning procedures between lots. Their flexibilities and speed are major selling points in today's highly competitive and time-sensitive environment for developing pharmaceuticals.

Opportunity for the Single Use Bioreactor Market

Expansion in Emerging Markets is significant opportunities in the global Single Use Bioreactor Market

The emerging economies of Brazil, India, and China represent a significant opportunity for the adoption of SUBs. These economies are investing in life sciences infrastructure and promoting local drug production. SUBs provide a cost-efficient and scalable alternative to firms in these economies to start or expand biomanufacturing capacity in a matter of months without the capital expense of conventional systems. Their portability, quick deployment, and low operation requirement make them an apt fit for economies establishing new biotech capacity.

Single Use Bioreactor Market Scope

Single Use Bioreactor Market Report Segmentation Analysis

The global Single Use Bioreactor Market industry analysis is segmented into by Product, by Type, by Usage Type by end-user and by region.

Single-use Bioreactor Systems hold major share In the Single Use Bioreactor Market

Single-use bioreactor systems represent the bulk of the total single-use bioreactor market because of their central role in facilitating bioproduction processes. They comprise a standard disposable bag, sensors, mixers, and control modules and have the ability to enable aseptic and efficient cell culture without the need for cleaning or sterilization. Their use is fueled by the increasing need for biologics and the biopharmaceutical industry's turn to more flexible and cost-saving manufacturing processes. These systems are very popular for both commercial and clinical manufacture because of their lower risk of cross-contamination, quicker setup times, as well as reduced costs of operation. In addition, evolution in bioprocess monitoring and automation has made single-use systems more advanced to enable high productivity without appreciable decline in product quality. Biotechnology firms and CMOs particularly enjoy having the capacity to perform multiple processes concurrently without significant infrastructure expenditures, positioning single-use systems as a pillar technology in flexible biomanufacturing settings.

Stirred-Tank SUBs type segment contributing major share in the Single Use Bioreactor Market

Stirred-tank single-use bioreactors (SUBs) are the most prevalent in the market, providing the largest market share due to their versatility, scalability, and compatibility in a broad range of cell cultures. Designed following conventional stainless-steel stirred-tank designs, the bioreactors blend the familiar mixing dynamics and the advantage of easily removable consumables. Stirred-tank SUBs have maximum efficiency in culturing mammalian cells used in the production of therapeutic proteins and monoclonal antibodies. They provide precise control of important parameters including oxygen levels, pH levels, and temperatures to yield reproducible and consistent conditions for the cultures. Stirred-tank SUBs are also scalable to pilot and commercial scales starting in the small laboratory volumes. They are also a top pick in various stages of drug development due to their ease of integration into routine work flows, minimal retraining requirement, and compatibility with a vast range of process analytics and monitoring tools. Stirred-tank SUBs' versatility and consistency in performance make this the preferred method for high-capacity biologic production in both industry and research.

Pilot-Scale Production Usage Type Dominating in Single Use Bioreactor Market

Pilot-scale production is a crucial step in biopharmaceutical development that bridges the gap between experimental work in the laboratory and commercial-scale production. In this process, single-use bioreactors (SUBs) are a key component that facilitates process optimization and qualification to a scale sufficient to predict industrial-scale performance but versatile to enable frequent adjustments. The prevalence of pilot-scale use in the market for SUBs stems from the fact that it is ideally suited for the testing of new medicines, biosimilars, and personalized treatments that need to be fast and flexible. SUBs on a pilot scale enable the manufacturer to reduce risk and cost by offering quicker batch turns and easier cleaning. They also facilitate the quick scale-up that a manufacturer needs to commercialize new treatments as rapidly as possible in a competitive or high-value market segment such as in oncology or vaccine manufacturing. They also enjoy preference in contract manufacturing organizations (CMOs) as well as biotech startups that work within a minimal infrastructure but need dependable, GMP-grade solutions. Their pilot-scale performance also enhances the probability of adoption to the commercial production stage in the biomanufacturing pipeline that validates their strategic role in the pipeline.

The following segments are part of an in-depth analysis of the global Single Use Bioreactor Market:

Single Use Bioreactor Market Share Analysis by Region

North America is projected to hold the largest share of the global Single Use Bioreactor Market over the forecast period.

North America will lead the global single-use bioreactor market because of the established biopharmaceutical sector there, advanced healthcare infrastructure in the region, and the high investment in research and development. North America has several major biopharmaceutical and biotech firms that actively embrace advanced bioprocess technologies, including single-use systems, to increase efficiency, shorten production duration, and ensure high-quality products. Government support and conducive regulatory frameworks also promote innovation and commercialization in biologics, fostering the need for versatile and scalable manufacturing technologies such as SUBs. The major presence of Thermo Fisher Scientific, Danaher Corporation, and GE Healthcare in the U.S. also helps the regional market grow as a result of ongoing product innovation and strategic collaboration. Further boosting the region’s SUB market in the aftermath of the pandemic have also been the rising rate of clinical trials and the region’s quick reaction to public healthcare needs—like the production of COVID-19 vaccines. Contract manufacturers and small biotechs in North America also favor single-use technologies due to cost-effectiveness, ease of operation, and high-operating flexibility.

 Market Competition Landscape Analysis

The market is competitive, with several established players and new entrants offering a range single use bioreactors product. Some of the key players Sartorius AG, Danaher Corporation, Thermo Fisher Scientific Inc., Merck KGaA, Eppendorf SE, Repligen Corporation, Lonza Group, ABEC Inc. and Others.

Global Single Use Bioreactor Market Recent Developments News:

• In April 2025, Thermo Fisher Scientific Inc. launched the 5L DynaDrive Single-Use Bioreactor (S.U.B.), broadening the range of bioreactors in the company. The 5L DynaDrive single-use bioreactor is designed to suit the varied needs of the larger biopharma, Contract Development and Manufacturing Organizations (CDMOs), as well as the small biotech firms. Its benchtop size and user-centric design make it possible to use with the HyPerforma G3Lab Controller to achieve very high levels of scalability and scalable proof of concept in a cost-effective way.
• In March 2025, Cytiva announced expansion of its Xcellerex X-platform line with the release of 500-L and 2000-L bioreactors. The additions will enable scientists and researchers to scale up the manufacture of next-generation advanced therapeutics more easily, starting from 50 L up to 2000 L.
• In June 2024, AGC Biologics finished a new manufacturing building on its Copenhagen campus. The expansion doubles the site's single-use bioreactor capacity for mammalian services to produce 150 more drug product batches a year. The expansion includes 19,000 square meters of new space in an ultramodern building featuring a large manufacturing floor space, added expanded quality control and process development laboratory space, utilities to facilitate all operations and avoid disruptions due to natural disasters, and a fully dedicated warehouse to support the whole AGC Copenhagen campus.

The global single use bioreactor market is dominated by a few large companies, such as

·         Sartorius AG

·         Danaher Corporation

·         Thermo Fisher Scientific Inc.

·         Merck KGaA

·         Eppendorf SE

·         Getinge AB

·         Pall Corporation

·         Repligen Corporation

·         Lonza Group

·         ABEC Inc.

·         Applikon Biotechnology

·         PBS Biotech Inc.

·         Distek Inc.

·         Saint-Gobain

·         OmniBRx Biotechnologies

·         Other Prominent Players